Laboratorios Farmaceuticos Rovi, SA

ROVI

Equity

ISIN ES0157261019 / Valor 3591807

BME Bolsas y Mercados Espanoles - Renta Variable (2024-09-16)

EUR 74.95+1.70%

Laboratorios Farmaceuticos Rovi, SA
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Laboratorios Farmaceuticos Rovi, SA, established in 1946, is a Spanish pharmaceutical company that specializes in the research, development, manufacture, and marketing of pharmaceutical products. Over the decades, the company has expanded its operations beyond Spain, achieving a significant international presence. Rovi's product portfolio includes both proprietary and licensed pharmaceutical products, with a notable focus on low-molecular-weight heparins, such as Bemiparin. The company has also ventured into contract manufacturing, offering services like production, filling, and packaging, particularly specializing in prefilled syringes and solid oral forms. Rovi places a strong emphasis on research and development, maintaining a solid and low-risk approach to innovation. In recent years, the company has been involved in significant agreements and collaborations with global pharmaceutical firms, and it played a role in the manufacturing process for the Moderna COVID-19 vaccine.

Summarized from source with an LLMView SourceSector: Healthcare

Operating Revenue

Laboratorios Farmaceuticos Rovi, SA reported operating revenue of €151.2 million for the first quarter of 2024. This represents a 25% decrease compared to the €201.6 million recorded in the first quarter of 2023. The decline was primarily attributed to lower revenues from the CDMO business, particularly related to the manufacture of the COVID-19 vaccine.

Gross Profit

The gross profit for Laboratorios Farmaceuticos Rovi, SA in the first quarter of 2024 was €85.6 million, down from €125.3 million in the same period of 2023. This 32% decrease was mainly due to the reduced sales from the COVID-19 vaccine production, which had previously contributed higher margins.

EBITDA and EBIT

Laboratorios Farmaceuticos Rovi, SA's EBITDA for Q1 2024 was €25.9 million, a significant drop from €66.5 million in Q1 2023, marking a 61% decrease. Similarly, EBIT fell by 68% to €19.3 million in the first quarter of 2024, compared to €60.7 million in the same period of the previous year.

Net Profit

The net profit for Laboratorios Farmaceuticos Rovi, SA in the first quarter of 2024 was €15.0 million, a 68% decrease from the €47.5 million reported in Q1 2023. The decline in net profit was influenced by the overall reduction in revenue and gross profit.

Capital Expenditures

Laboratorios Farmaceuticos Rovi, SA increased its capital expenditures (Capex) to €9.0 million in the first quarter of 2024, up from €4.9 million in Q1 2023. This 83% increase reflects the company's ongoing investments in property, plant, and equipment, as well as intangible assets.

Summarized from source with an LLMView Source

Key figures

36.4%1Y

32.2%3Y

259%5Y

Performance

26.6%1Y

35.2%3Y

34.5%5Y

Volatility